Skip to main content

KabiCare Patient Support Program forSTIMUFEND® (pegfilgrastim-fpgk)

Stimufend Box Packaging and Injection Syringe

STIMUFEND® is FDA approved and is indicated to decrease the incidence of infection in patients whose immune system is weakened due to chemotherapy for certain types of cancers.  STIMUFEND is also FDA approved and is indicated to increase survival in patients whose immune system is weakened due to acute exposure to myelosuppressive doses of radiation.

Acute Radiation Syndrome: The effectiveness of pegfilgrastim for this use was only studied in animals, because it could not be studied in people.

Learn more about Febrile Neutropenia.

For more information about Biosimilars please visit our website: BioSpecialized (Opens in a New Window)

Important Safety Information

Program Support Areas

Learn more about the program support for STIMUFEND (pegfilgrastim-fpgk) offered through KabiCare by selecting an area of support below:

KabiCare is here to offer you support and assistance, from diagnosis through your treatment and care.

There are several ways to enroll in the programs provided by KabiCare. Your healthcare provider can enroll you in the KabiCare Patient Support Program or you can download the enrollment form (PDF Opens in a New Window) and begin completing it yourself. Once enrolled, patients can opt-in for clinical support and note any communication preferences that the KabiCare Patient Support Guide should be aware of.

Talk to your doctor today about enrolling in KabiCare.

Who is Your Patient Support Guide?

Your KabiCare Patient Support Guide will work closely with you and your healthcare provider(s) to help navigate your insurance, financial assistance, and medication access needs to simplify your treatment journey. Getting answers to your questions is just a phone call away at 1.833.KABICARE.

New Patient Information

A patient brochure will be mailed to you once your enrollment is complete. Inside the brochure you will find ways to access important information about your medication and other resources available to you while on your treatment.

After enrollment in KabiCare is complete, you will receive a Welcome Call from a Patient Support Guide, where you will have an opportunity to review your benefits and discuss other patient support program offerings you may be eligible to receive.

Bridge to Therapy Program
The Bridge to Therapy Program ensures that you can receive STIMUFEND without delay while you are waiting for insurance approval. Eligibility* criteria apply.

*Eligibility criteria apply. Patients are not eligible for Bridge to Therapy Program support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.

KabiCare can help with enrolling you into additional assistance programs.

Commercial Copay Support

If you have commercial or private insurance, you may be eligible* for the copay program that lowers your out-of-pocket costs to as little as $0/month for treatment with an annual maximum.

Learn more about the copay program or enroll in copay ONLY

Patient Assistance Program

If you do not have insurance and/or cannot afford your medication, you may be eligible for additional assistance through the Patient Assistance Program** or through independent nonprofit patient assistance programs. Eligibility criteria apply.‡

*Eligibility criteria apply. Patients are not eligible for commercial copay assistance if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.

**Terms and Conditions apply.

‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.

Clinical Support

Once you are enrolled, you will have the opportunity to speak with a professional Clinician to help you understand your disease, treatment, and prescribed medication. They can provide additional educational resources to you as needed or requested.

Clinical support provided by KabiCare is not meant to replace discussions with your healthcare provider regarding your care and treatment.

Transportation and Lodging

KabiCare will investigate potential transportation and lodging benefits that may be offered by your insurance. A list of independent foundations** is provided when treatment-related transportation and lodging assistance are needed.

**Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.

About Febrile Neutropenia

What is Neutropenia?

Neutrophils are a type of white blood cell. White blood cells are part of your immune system. Neutrophils play an important role in your body’s defense against infection.  Cancer treatment, such as chemotherapy, can decrease your body’s number of neutrophils because chemotherapy kills both normal cells (such as immune cells) and abnormal cells (cancer).1,2,3 Neutropenia occurs when you have a lower than normal level of neutrophils.1,2 Unfortunately, 60,000 people with cancer are hospitalized due to neutropenia each year in the US.3

What is Febrile Neutropenia?

Febrile neutropenia is when neutropenia is accompanied by a fever. For many people with cancer, suffering from neutropenia is the greatest risk factor for getting a serious infection. These infections can become serious or life-threatening if not found and treated early.3 As a result, if you have a low neutrophil count, your cancer team may have to delay or discontinue your cancer treatment or reduce your dose to prevent worsening neutropenia.1,2,4

Learn more about Febrile Neutropenia.

Febrile Neutropenia Resources

Here you will find useful resources that may help support you during your treatment journey.

Tips and helpful Downloadable resources:

Useful website links:

For more information about support groups or a list of independent foundations

Please visit the STIMUFEND website for additional product and treatment information. (Opens in a New Window)

Healthcare Professional Speaking with a Patient

Why Enroll in KabiCare?

KabiCare is here to offer you support and assistance, from diagnosis through your treatment and care.

There are several ways to enroll in the programs provided by KabiCare. Your healthcare provider can enroll you online in the KabiCare Patient Support Program or by fax. Once enrolled, patients can note any communication preferences that the KabiCare Patient Support Guide should be aware of.

Talk to your doctor today about enrolling in KabiCare.

References

  1. JAMA Oncol. 2017;3(12):1751. doi:10.1001/jamaoncol.2017.1114 Febrile Neutropenia | Oncology | JAMA Oncology | JAMA Network (Opens in a New Window). Accessed August 26, 2024.
  2. Low White Blood Cell Counts (Neutropenia). American Cancer Society website. Updated February 1, 2020. Updated February 6, 2024. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/neutropenia.html# (Opens in a New Window)
  3. Top 5 things to know about neutropenia. US Department of Health and Human Services Center for Disease Control and Prevention website. Accessed August 26, 2024. https://www.preventcancerinfections.org/sites/default/files/14_250329-Patient-Infographic-15_508_FINAL_2.jpg (JPG Opens in a New Window)
  4. Crawford, J. Risk Assessment and Guidelines for First-Cycle Colony-Stimulating Factor Use in the Management of Chemotherapy-Induced Neutropenia. Oncology. 2006;20(5):Suppl4. PMID:16736985.
Expand

WHAT IS STIMUFEND® (pegfilgrastim-fpgk)?

STIMUFEND is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

IMPORTANT SAFETY INFORMATION

Do not take Stimufend if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Stimufend, tell your healthcare provider about all of your healthcare conditions, including if you:

  • Have a sickle cell disorder
  • Are allergic to latex – The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
  • Have kidney problems
  • Are pregnant or plan to become pregnant. It is not known if Stimufend may harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Stimufend passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Warnings and Precautions

  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Stimufend. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Stimufend can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating. Call your healthcare provider or get emergency medical help right away if you have any of these symptoms.
  • Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Stimufend. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
  • Kidney injury (glomerulonephritis). Stimufend can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Stimufend.
  • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with Stimufend. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Stimufend. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
  • Capillary Leak Syndrome. Stimufend can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • Swelling or puffiness and are urinating less than usual
    • Trouble breathing
    • Swelling of your stomach area (abdomen) and feeling of fullness
    • Dizziness or feeling faint
    • A general feeling of tiredness
  • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when Stimufend is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Stimufend.
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Stimufend. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Stimufend is pain in your bones and in your arms and legs.

These are not all the possible side effects of Stimufend. Call your healthcare provider for medical advice about side effects. You may report negative side effects to the FDA at 1-800-FDA-1088.

Please see Stimufend Patient Information (PDF Opens in a New Window).

Stimufend Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Indication

Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use

Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

WHAT IS STIMUFEND® (pegfilgrastim-fpgk)?

STIMUFEND is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body’s fight against infection.

IMPORTANT SAFETY INFORMATION

Do not take Stimufend if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Stimufend, tell your healthcare provider about all of your healthcare conditions, including if you:

  • Have a sickle cell disorder
  • Are allergic to latex – The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
  • Have kidney problems
  • Are pregnant or plan to become pregnant. It is not known if Stimufend may harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Stimufend passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Warnings and Precautions

  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Stimufend. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Stimufend can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating. Call your healthcare provider or get emergency medical help right away if you have any of these symptoms.
  • Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Stimufend. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
  • Kidney injury (glomerulonephritis). Stimufend can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Stimufend.
  • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with Stimufend. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Stimufend. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
  • Capillary Leak Syndrome. Stimufend can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • Swelling or puffiness and are urinating less than usual
    • Trouble breathing
    • Swelling of your stomach area (abdomen) and feeling of fullness
    • Dizziness or feeling faint
    • A general feeling of tiredness
  • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when Stimufend is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Stimufend.
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Stimufend. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Stimufend is pain in your bones and in your arms and legs.

These are not all the possible side effects of Stimufend. Call your healthcare provider for medical advice about side effects. You may report negative side effects to the FDA at 1-800-FDA-1088.

Please see Stimufend Patient Information (PDF Opens in a New Window).

Stimufend Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Indication

Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use

Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.